4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine - CAS 16372-08-0
Catalog: |
BB012029 |
Product Name: |
4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine |
CAS: |
16372-08-0 |
Synonyms: |
5H-Pyrrolo[2,3-d]pyrimidine, 4-chloro-6,7-dihydro-; Tofacitinib Impurity 07 |
IUPAC Name: | 4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine |
Description: | One of the impurities of Tofacitinib, which is a Janus kinase inhibitor and could be used against rheumatoid arthritis. |
Molecular Weight: | 155.58 |
Molecular Formula: | C6H6ClN3 |
Canonical SMILES: | C1CNC2=C1C(=NC=N2)Cl |
InChI: | InChI=1S/C6H6ClN3/c7-5-4-1-2-8-6(4)10-3-9-5/h3H,1-2H2,(H,8,9,10) |
InChI Key: | LJXVPXRXXVHTBP-UHFFFAOYSA-N |
Boiling Point: | 252.4±50.0 °C at 760mmHg |
Melting Point: | 164-166°C |
Purity: | 97% |
Density: | 1.63±0.1 g/cm3 |
Solubility: | Soluble in DMSO (Slightly), Methanol (Slightly) |
Appearance: | Pale Tan Solid |
Storage: | Store at -20°C |
MDL: | MFCD11518925 |
LogP: | 1.61130 |
Publication Number | Title | Priority Date |
KR-20210015730-A | Oxo-pyridine fused ring derivatives and pharmaceutical composition containing the same | 20190802 |
WO-2021025407-A1 | Oxo-pyridine fusion ring derivative and pharmaceutical composition comprising same | 20190802 |
CN-112047932-A | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 20190605 |
WO-2020070181-A1 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer | 20181002 |
EP-3860990-A1 | Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer | 20181002 |
Complexity: | 130 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 0 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 155.0250249 |
Formal Charge: | 0 |
Heavy Atom Count: | 10 |
Hydrogen Bond Acceptor Count: | 3 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 155.0250249 |
Rotatable Bond Count: | 0 |
Topological Polar Surface Area: | 37.8 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 1.5 |
-
Catalog: BB047664
(1E)-3-(4-Chloro-1H-pyrazol-1-yl)-N'-hydroxy-2-methylpropanimidamide
Detail
-
Catalog: BB051699
(1-(2,2-Difluoroethyl)-1H-pyrazol-4-yl)methanamine hydrochloride
Detail
-
Catalog: BB025409
(1-Bromo-2,2,2-trifluoroethyl)benzene
Detail
-
Catalog: BB054256
((2S,4R)-2-((1H-1,2,4-Triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methanol
Detail
-
Catalog: BB044292
(+)-(8,8-Dichlorocamphorylsulfonyl)oxaziridine
Detail
-
Catalog: BB044156
(-)-2,10-(3,3-dichlorocamphorsultam)
Detail
-
Catalog: BB078021
(1-(3-Bromo-5-fluorophenyl)cyclopropyl)methanamine
Detail
-
Catalog: BB017138
(1-Bromo-3-chloropropyl)benzene
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Halides
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS